1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Primary Immune Deficiency (PID)-Pipeline Insights, 2016

Primary Immune Deficiency (PID)-Pipeline Insights, 2016

  • November 2016
  • -
  • Delve Insight
  • -
  • 60 pages


DelveInsight’s, “ Primary Immune Deficiency (PID)-Pipeline Insights, 2016”, report provides in depth insights on the pipeline drugs and their development activities around the Primary Immune Deficiency (PID). The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Primary Immune Deficiency (PID). DelveInsight’s Report also assesses the Primary Immune Deficiency (PID) therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope
- The report provides competitivepipeline landscape of Primary Immune Deficiency (PID)
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Primary Immune Deficiency (PID) pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Primary Immune Deficiency (PID) and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Table Of Contents

Primary Immune Deficiency (PID)-Pipeline Insights, 2016

Illustrative Table of contents

- Primary Immune Deficiency (PID) Overview
- Primary Immune Deficiency (PID) Pipeline Therapeutics
- Primary Immune Deficiency (PID) Therapeutics under Development by Companies
- Primary Immune Deficiency (PID) Filed and Phase III Products
- Comparative Analysis
- Primary Immune Deficiency (PID) Phase II Products
- Comparative Analysis
- Primary Immune Deficiency (PID) Phase I and IND Filed Products
- Comparative Analysis
- Primary Immune Deficiency (PID) Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Primary Immune Deficiency (PID) - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Primary Immune Deficiency (PID) - Discontinued Products
- Primary Immune Deficiency (PID) - Dormant Products
- Companies Involved in Therapeutics Development for Primary Immune Deficiency (PID)
- Appendix
- Methodology
- Contact Us
- Disclaimer

List of Tables

- Number of Products under Development for Primary Immune Deficiency (PID), 2016
- Number of Products under Development by Companies
- Comparative Analysis by Filed and Phase III Products, 2016
- Comparative Analysis Phase II Products, 2016
- Comparative Analysis Phase I and IND Filed Products, 2016
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2016
- Drug Candidates Profiles
- Primary Immune Deficiency (PID) Assessment by Monotherapy Products
- Primary Immune Deficiency (PID) Assessment by Combination Products
- Primary Immune Deficiency (PID) Assessment by Route of Administration
- Primary Immune Deficiency (PID) Assessment by Stage and Route of Administration
- Primary Immune Deficiency (PID) Assessment by Molecule Type
- Primary Immune Deficiency (PID) Assessment by Stage and Molecule Type
- Primary Immune Deficiency (PID) Therapeutics - Discontinued Products
- Primary Immune Deficiency (PID) Therapeutics - Dormant Products
- Products under Development by Companies, 2016

List of Figures

- Number of Products under Development for Primary Immune Deficiency (PID), 2016
- Filed and Phase III Products, 2016
- Phase II Products, 2016
- Phase I and IND Filed Products, 2016
- Discovery and Pre-Clinical Stage Products, 2016
- Primary Immune Deficiency (PID) Assessment by Monotherapy Products
- Primary Immune Deficiency (PID) Assessment by Combination Products
- Primary Immune Deficiency (PID) Assessment by Route of Administration
- Primary Immune Deficiency (PID) Assessment by Stage and Route of Administration
- Primary Immune Deficiency (PID) Assessment by Molecule Type
- Primary Immune Deficiency (PID) Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Global Genetic disorders Partnering 2010-2016: Deal trends, players and financials

Global Genetic disorders Partnering 2010-2016: Deal trends, players and financials

  • $ 2995
  • Industry report
  • November 2016
  • by Currentpartnering

Global Genetic Disorders Partnering 2010 to 2016 provides the full collection of Genetic Disorders disease deals signed between the world’s pharmaceutical and biotechnology companies since 2010. Trends ...

Chediak-Higashi Syndrome Global Clinical Trials Review, H2, 2016

Chediak-Higashi Syndrome Global Clinical Trials Review, H2, 2016

  • $ 2500
  • Industry report
  • August 2016
  • by Global Data

Chediak-Higashi Syndrome Global Clinical Trials Review, H2, 2016 Summary GlobalData's clinical trial report, “Chediak-Higashi Syndrome Global Clinical Trials Review, H2, 2016" provides an overview of ...

Alpha-Mannosidosis Global Clinical Trials Review, H2, 2016

Alpha-Mannosidosis Global Clinical Trials Review, H2, 2016

  • $ 2500
  • Industry report
  • August 2016
  • by Global Data

Alpha-Mannosidosis Global Clinical Trials Review, H2, 2016 Summary GlobalData's clinical trial report, “Alpha-Mannosidosis Global Clinical Trials Review, H2, 2016" provides an overview of Alpha-Mannosidosis ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.